🏛️ Verified NIH Record • Updated 2026-01-06
MT2017-45: CAR-T Cell Therapy for Heme Malignancies (NCT03642626)
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients With Hematologic Malignancies
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Masonic Cancer Center, University of Minnesota
🩺 Plain-English Summary (8th-Grade Level)
This is a phase II study of FDA-approved CAR-T products for patients with hematologic malignancies. Patients will be assigned to Arm A and B based on age and diagnosis. Overall remission rate, safety events and other endpoints will be calculated for Arm A and B separately.
Who can join: Review the eligibility criteria below.
Location: Masonic Cancer Center at University of Minnesota — Minneapolis, Minnesota
🧪 Interventions in This Study
- KYMRIAH (DRUG)
- YESCARTA (DRUG)
- Fludarabine 30mg/m2 4 doses (DRUG)
- Cyclophosphamide 500 mg/m2; 2 doses (DRUG)
- Fludarabine 30mg/m2 3 doses (DRUG)
- Cyclophosphamide 500 mg/m2; 3 doses (DRUG)
- Fludarabine 25mg/m2 3 days (DRUG)
- Cyclophosphamide 250 mg/m2; 3 days (DRUG)
- Tecartus (DRUG)
- Abecma, Intravenous Suspension (DRUG)
- Cyclophosphamide 900 mg/m2; 1 day (DRUG)
- Breyanzi Injectable Product (DRUG)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Masonic Cancer Center at University of Minnesota — Minneapolis, Minnesota
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Lymphoblastic Leukemia
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — Birmingham, Alabama
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia — Birmingham, Alabama
- Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia — Duarte, California
- Transcranial Direct Current Stimulation of the Temporal Cortex in Survivors of Childhood Acute Lymphoblastic Leukemia (ALL) — Memphis, Tennessee
- Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy — Duarte, California
- Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease — Houston, Texas
Explore by condition: All Acute Lymphoblastic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.